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AUTHOR SUMMARY
LESSONS LEARNED
x Despite evidence for a role for prolactin signaling in breast and prostate tumorigenesis, a prolactin receptor-bindingmonoclonal
antibody has not produced clinical efficacy.
x Increased serum prolactin levels may be a biomarker for prolactin receptor inhibition.
x Results from the pharmacokinetic and pharmacodynamics (PD) studies suggest that inappropriately long dosing intervals and
insufficient exposure to LFA102 may have resulted in lack of antitumor efficacy.
x Based on preclinical data, combination therapy of LFA102 with those novel agents targeting hormonal pathways in metastatic
castration-resistant prostate cancer and metastatic breast cancer is promising.
x Given the PD evidence of prolactin receptor blockade by LFA102, this drug has the potential to be used in conditions such as
hyperprolactinemia that are associated with high prolactin levels.
ABSTRACT
Background. Prolactin receptor (PRLR) signaling is impli-
cated in breast and prostate cancer. LFA102, a humanized
monoclonal antibody (mAb) that binds to and inhibits
the PRLR, has exhibited promising preclinical antitumor
activity.
Methods. Patients with PRLR-positive metastatic breast
cancer (MBC) or metastatic castration-resistant prostate
cancer (mCRPC) received doses of LFA102 at 3–60 mg/kg
intravenously once every 4 weeks. Objectives were to
determine the maximum tolerated dose (MTD) and/or
recommended dose for expansion (RDE) to investigate
the safety/tolerability of LFA102 and to assess pharmaco-
kinetics (PK), pharmacodynamics (PD), and antitumor
activity.
Results. A total of 73 patients were enrolled at 5 dose levels.
The MTD was not reached because of lack of dose-limiting
toxicities. The RDE was established at 60 mg/kg based on PK
and PD analysis and safety data. The most common all-cause
adverse events (AEs) were fatigue (44%) and nausea (33%)
regardless of relationship. Grade 3/4 AEs reported to be
related to LFA102occurred in 4%of patients. LFA102 exposure
increased approximately dose proportionally across the doses
tested. Serumprolactin levels increased in response to LFA102
administration, suggesting itspotential asabiomarker forPRLR
inhibition. No antitumor activity was detected.
Conclusion.TreatmentwithLFA102wassafeandwell tolerated,
but did not show antitumor activity as monotherapy at the
doses tested. The Oncologist 2016;21:535–536
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DISCUSSION
Prolactin, a pituitary-derived polypeptide hormone, is impli-
cated in breast and prostate tumorigenesis. Expression of the
PRLR has been confirmed in breast and prostate cancers. This
phase I study evaluated LFA102 in 73 patients with PRLR-
positive MBC or mCRPC, treated at doses of 3–60 mg/kg.
Duringdoseescalation, LFA102demonstrated favorable safety
and tolerability at all doses. No dose-limiting toxicities (DLTs)
occurred; therefore, the MTD was not reached, although the
RDE was established at 60 mg/kg based on safety, PK, and PD
data supported by Bayesian logistic regression modeling. Dose
proportionality analysis showed that serum LFA102 maximum
concentration observed (Cmax) and area under the last mea-
surable concentration (AUClast) were approximately linearly
dose dependent (Fig. 1) and should provide sufficient expo-
sure toachieveefficacy.However,noobjective responseswere
observed in patients with MBC, and in patients with mCRPC,
there were no prostate-specific antigen (PSA) responses.
Invitrodatahaveshownahighbindingaffinityof LFA102 to
PRLR, but because assessing LFA102 binding within tumors is
impractical inpatients, ourstudyusedserumprolactin levelsas
a surrogate marker for PRLR inhibition. A sixfold change in
serum prolactin levels from baseline was observed in patients
treatedwith LFA102 60mg/kg, indicative of inhibition of PRLR
and ruling out poor target binding as causing lack of efficacy
(Fig. 2). Other potential explanations for the lack of LFA102
efficacy include that prolactin may not be an oncogenic
driver in breast and prostate cancer in humans, unforeseen
compensatory modulation of downstream signaling path-
ways in response toPRLR inhibition, orupregulationofother
tumorigenic signaling pathways that compensate for PRLR
inhibition. Nevertheless, preclinical data show that letro-
zole potentiates the efficacy of LFA102 when administered
in combination in a rat mammary cancer model. Therefore,
although LFA102 monotherapy may not show antitumor
activity, itmayhavepotential for treatingprolactin-dependent
tumors in combination with other recently approved, novel
hormonal pathway targeting agents in MBC and mCRPC.
Furthermore, given the PD evidence of prolactin receptor
blockade by LFA102, this drug has the potential to be used in
conditions such as hyperprolactinemia that are associated
with high prolactin levels.
Author disclosures available online.
EDITOR’S NOTE: See the related commentary, “Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and
Prostate Cancer,” by Ciara C. O’Sullivan and Susan E. Bates on page 523 of this issue.
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Figure 1. AUClast and Cmax increase with LFA102 dose in a
relatively proportionalmanner. AUClast (A) and Cmax (B) results for
individual patients in cycle 1. For each dose, parameter values
(open symbols), least-square mean (black triangles), and 90%
least-squaremeans confidence interval (vertical bars) are shown.
Serum LFA102 concentrations were measured up to day 28 of
cycle 1 via dense sampling followed by trough concentration
measurement in subsequent cycles. Concentration-time profiles
showbiexponential disposition typical formonoclonal antibodies.
Cmax and AUClast increased in a relatively proportional manner
with increasing LFA102 doses.
Abbreviations: AUClast, area under the last measurable concen-
tration; Cmax, maximum concentration observed.
Figure 2. Serum prolactin levels rise with increasing doses of
LFA102. Linear views of individual serum prolactin concentration-
time profiles grouped by LFA102 dose group are shown.
Individual patient serum prolactin increased after LFA102
administration.
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